Inventor · disambiguated record
Wolf-Nicolas Fischer
Also filed as: FISCHER WOLF-NICOLAS
13 granted patents·8 pending applications·63 citations·filing 2001–2025
89Inventor score
Files withQUADRIGA BIOSCIENCES INC13JANDELEIT BERND2MAXYMUNE THERAPEUTICS INC2XENOPORT INC2SEPELO THERAPEUTICS LLC1
Top patents by PatentIndex Score
21 records- 0195US9394237B2β-substituted β-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2015·Granted Jul 19, 2016·13 cites·24 claims
- 0293US7994218B2Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of useXENOPORT INC·Filed 2008·Granted Aug 9, 2011·14 cites·21 claims
- 0392US9861599B2Beta-substituted beta-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2016·Granted Jan 9, 2018·4 cites·21 claims
- 0490US8168617B2Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of useJANDELEIT BERND·Filed 2008·Granted May 1, 2012·24 cites·25 claims
- 0589US9783487B2Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereofQUADRIGA BIOSCIENCES INC·Filed 2016·Granted Oct 10, 2017·8 cites·25 claims
- 0673US2025339388A1Phenylalanine-based lat1 inhibitors and uses thereofMAXYMUNE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0765US10245246B2β-substituted β-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2017·Granted Apr 2, 2019·0 cites·11 claims
- 0865US2016296484A1Beta-substituted beta-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 0962US12427124B1Phenylalanine-based LAT1 inhibitors and uses thereofMAXYMUNE THERAPEUTICS INC·Filed 2025·Granted Sep 30, 2025·0 cites·28 claims
- 1062US10246406B2Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereofQUADRIGA BIOSCIENCES INC·Filed 2018·Granted Apr 2, 2019·0 cites·24 claims
- 1161US2019185413A1Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereofQUADRIGA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 1260US10017459B2β-substituted β-amino acids and analogs as chemotherapeutic agents and uses thereofQUADRIGA BIOSCIENCES INC·Filed 2017·Granted Jul 10, 2018·0 cites·21 claims
- 1359US10034847B2Beta-substituted beta-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2016·Granted Jul 31, 2018·0 cites·15 claims
- 1457US9937139B2β-substituted γ-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2017·Granted Apr 10, 2018·0 cites·9 claims
- 1554US9682921B2β-substituted γ-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2016·Granted Jun 20, 2017·0 cites·10 claims
- 1654US2009099253A1Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of UseXENOPORT INC·Filed 2008·Application pending·0 cites
- 1754US2023285572A1Targeted delivery of therapeutic agentsSEPELO THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 1847US2009082464A1Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of useJANDELEIT BERND·Filed 2008·Application pending·0 cites
- 1946US9394236B2β-substituted γ-amino acids and analogs as chemotherapeutic agentsQUADRIGA BIOSCIENCES INC·Filed 2015·Granted Jul 19, 2016·0 cites·55 claims
- 2043US2016346240A1Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogsQUADRIGA BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 2137US2004096424A1Modification of gene expression in transgenic plantsFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wolf-Nicolas Fischer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →